赵瑜，1984年出生，籍贯山东，中国医学科学院放射医学研究所研究员，博士生导师。2002年考入青岛大学生物化学专业，获得学士学位。2007年在南开大学攻读博士学位，从事生物化学与分子生物学研究。2012年进入梅奥医院攻读博士后，并于2018年任梅奥医院研究助理。2020年进入中国医学科学院放射医学研究所工作，2021年升为研究员。

基于抗肿瘤药物机制的研究和基于反义寡核苷酸(ASO)合成技术开发肿瘤核素靶向药物两方面的突破性进展，主要从事肿瘤表观遗传学、放射表观遗传与转录调控、RNA药物研发等领域的基础研究和产品技术研发工作。

1. Li Y#, Wang C#, Gao H#, Gu J, Zhang Y, Zhang Y, Xie M, Cheng X, Yang M, Zhang W, Li Y, He M, Xu H, Zhang H, Ji Q, Ma T, Ding S, Zhao Y*, Gao Y*. KDM4 inhibitor SD49-7 attenuates leukemia stem cell via KDM4A/MDM2/p21CIP1 axis. Theranostics. 2022 Jun 21;12(11):4922-4934. (IF=11.600)

2. Chen L#, Liu H, Ji Y, Ma Z, Shen K, Shangguan X, Qian H, Zhao Y*, Pan CW*, Xue W*. Downregulation of SHMT2 promotes the prostate cancer proliferation and metastasis by inducing epithelial-mesenchymal transition. Exp Cell Res. 2022 Jun 15;415(2):113138.  (IF=4.145)

3. Pan CW#, Wen S, Chen L, Wei Y, Niu Y, Zhao Y. Functional roles of antisense enhancer RNA for promoting prostate cancer progression. Theranostics. 2021 Jan 1;11(4):1780-1794.  (IF=11.600)

4. Wen S#, Wei Y#, Zen C, Xiong W, Niu Y*, Zhao Y*. Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine. Mol Cancer. 2020 Dec 12;19(1):171.  (IF=41.444)

5. Zhao Y#, Ding L, Wang D, Ye Z, He Y, Ma L, Zhu R, Pan Y, Wu Q, Pang K, Hou X, Weroha SJ, Han C, Coleman R, Coleman I, Karnes RJ, Zhang J, Nelson PS, Wang L, Huang H. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. EMBO J. 2019 Mar 1;38(5):e99599.  (IF=14.012)

6. He Y#, Zhao Y#, Wang L#, Bohrer LR, Pan Y, Wang L, Huang H. LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation. Oncogene. 2018 Jan 25;37(4):534-543.  (IF=8.756)

7. Zhang P#, Wang D#, Zhao Y#, Ren S#, Gao K#, Ye Z, Wang S, Pan CW, Zhu Y, Yan Y, Yang Y, Wu D, He Y, Zhang J, Lu D, Liu X, Yu L, Zhao S, Li Y, Lin D, Wang Y, Wang L, Chen Y, Sun Y*, Wang C*, Huang H*. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med. 2017 Sep;23(9):1055-1062.  (IF=87.241)

8. Zhao Y#, Wang L, Ren S, Wang L, Blackburn PR, McNulty MS, Gao X, Qiao M, Vessella RL, Kohli M, Zhang J, Karnes RJ, Tindall DJ, Kim Y, MacLeod R, Ekker SC, Kang T, Sun Y*, Huang H*. Activation of P-TEFb by androgen receptor-Regulated enhancer RNAs in castration-Resistant prostate cancer. Cell Rep. 2016 Apr 19;15(3):599-610.  (IF=9.995)

9. Zhao Y#, Li H#, Zhang Y, Li L, Fang R, Li Y, Liu Q, Zhang W, Qiu L, Liu F, Zhang X*, Ye L*. Oncoprotein HBXIP modulates abnormal lipid metabolism and growth of breast cancer cells by activating the LXRs/SREBP-1c/FAS signaling cascade. Cancer Res. 2016 Aug 15;76(16):4696-707.  (IF=13.312)

10. Zhao Y#, Tindall DJ, Huang H. Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer. Int J Biol Sci. 2014 Jun 5;10(6):614-9.  (IF=10.750)